Clinical trials: End Stage Liver Disease
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
End Stage Renal Disease on Hemodialysis (Diagnosis)
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
This is an open-label, single arm study design to evaluate HEPLISAV-B® in adults with ESRD who are initiating or undergoing hemodialysis.
- Trial name
- NCT03934736
- Testing
- HEPLISAV-B®
- Where
- 20 sites in United States
- Volunteers
- 119 people
- Sponsor
- Dynavax Technologies Corporation
Urea Cycle Disorder, Crigler-Najjar Syndrome
HepaStem Long-Term Safety Registry
All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences
- Conditions
- Urea Cycle Disorder, Crigler-Najjar Syndrome, Acute on Chronic Liver Failure
- Trial name
- PROLONGSTEM (NCT03343756)
- Where
- 29 sites in Belgium, Bulgaria and 3 more
- Volunteers
- 44 people
- Sponsor
- Cellaion SA
Liver Failure, Acute on Chronic, Liver Injury
A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China
The definition and diagnostic criteria of Acute-on-chronic liver failure (ACLF) has been well established by EASL CANONIC study. However, patients with high risk to develop ACLF has not been determined, yet.
- Trial name
- NCT03281265
- Testing
- standard treatment
- Volunteers
- 1,178 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Liver Failure, Acute Liver Injury, Drug Induced
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure.
- Conditions
- Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
- Trial name
- NCT06285253
- Testing
- miroliverELAP treatment
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Miromatrix Medical Inc.
28 Day Mortality
Thromboelastography Guides a Multicentre Cluster Controlled Study of Plasma Exchange for Hepatitis B Associated Acute-on-chronic Liver Failure
In the past ten years, the extracorporeal liver support system has been widely used in clinical practice as a first-line treatment of liver failure.
- Trial name
- NCT04747106
- Testing
- plasma exchange
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute-On-Chronic Liver Failure
Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients
The goal of this clinical trial is to learn if CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection (hereinafter referred to as CG-BM1) can treat acute-on-chronic liver failure (ACLF) patients.
- Trial name
- NCT06740149
- Testing
- Bone marrow mesenchymal stem cells (low dose), Solvent of CG-BM1, Bone marrow mesenchymal stem cells (medium dose)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.
Acute on Chronic Liver Failure
Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)
SIRS in ACLF exacerbate adverse effects of ammonia - sarcopenia, infections, immune dysfunction, HE and organ dysfunction Persistent or incident hyperammonemia during first week of hospitalization in patients with ACLF is…
- Trial name
- NCT06808009
- Testing
- Lactulose, Rifaximin, Standard Medical treatment
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Failure
Nomogram Analysis for HBV Related Acute-on-chronic Liver Failure
Acute-on-chronic liver failure (ACLF) is an acute deterioration of chronic liver diseases, which progresses rapidly, with a mortality rate of more than 50%.MELD score is used to evaluate the patients' condition.
- Trial name
- NCT03992898
- Testing
- No special intervention was suitable for this observational study
- Where
- China
- Volunteers
- 2,739 people
- Sponsor
- Sun Yat-sen University
Liver Transplantation, Total Parenteral Nutrition
Supplements SMOF in TPN for Liver Transplantation Recipients
Liver transplantation (LT) is one of the widely recognised and leading treatments for end-stage liver disease. Nutrition impacts its success.
- Conditions
- Liver Transplantation, Total Parenteral Nutrition, End-stage Liver Disease
- Trial name
- NCT04572373
- Testing
- SMOFlipid
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- Chang Gung Memorial Hospital
Acute-On-Chronic Liver Failure
Platelet Transfusion in Acute-on Chronic Liver Failure
Acute on-chronic liver failure (ACLF) is a severe liver disease with a 28-day mortality rate of up to 40%. When the patients get 3 or more organ failures, the 28-day mortality rate is up to 82.6%.
- Trial name
- NCT04564651
- Testing
- platelet transfusion
- Where
- 8 sites in China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
- Trial name
- CONTROL-ACLF (NCT07694297)
- Testing
- NTZ 500mg BID on top of SOC
- Volunteers
- 16 people
- Sponsor
- Genfit
Hepatitis C
Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not…
- Trial name
- NCT01429155
- Testing
- Interleukin 28B genotype
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Henry Ford Health System
Cirrhosis, Hepatic Encephalopathy
Factors Associated With End Stage Liver Disease
100 ambulatory cirrhotic patients attending a liver transplant clinic will undergo a comprehensive clinical evaluation for severity of liver disease, anemia, depression, and fatigue.
- Conditions
- Cirrhosis, Hepatic Encephalopathy, Fatigue, Depression
- Trial name
- NCT01846819
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Chronic Liver Failure
Aerobic Capacity Muscle Strength and Health Related Quality of Life in Children With Chronic Liver Disease
Physical therapy program for children with chronic liver disease consist of gait training, strengthening ex for UL\&ll, stretching exercise to improve physical fitness and quality of life
- Trial name
- NCT06240832
- Testing
- Physical therapy exercise
- Where
- Egypt
- Volunteers
- 18 people
- Sponsor
- Cairo University
End Stage Liver DIsease, Sarcopenia
Adverse Outcomes and Mortality in Liver Transplant
Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.
- Conditions
- End Stage Liver DIsease, Sarcopenia, Sarcopenic Obesity, Cirrhosis
- Trial name
- NCT05477277
- Testing
- MAsS
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Liver Diseases, Hepatocellular Cancer
Adult-to-Adult Living Donor Transplant Cohort Study
The study is being conducted for the following reasons: 1. To determine the prevalence, course, and predictors of poor Health Related Quality of Life (HRQOL) outcomes associated with living donor donation. 2.
- Conditions
- Liver Diseases, Hepatocellular Cancer, End Stage Liver Disease, Hepatitis C
- Trial name
- A2ALL-2 (NCT01619475)
- Where
- 9 sites in United States, Canada
- Volunteers
- 1,871 people
- Sponsor
- Arbor Research Collaborative for Health
End-stage Liver Disease (ESLD), Acute Liver Failure
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given…
- Conditions
- End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
- Trial name
- REFRAME-MP (NCT07585890)
- Testing
- Endischemic hypothermic oxygenated machine perfusion (any device), Endischemic (back-to-base) normothermic machine perfusion (any device), Continuous (device-to-donor) normothermic machine perfusion (any device)
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 10,000 people
- Sponsor
- University Medical Center Groningen
Hepatitis C Virus Infection, Response to Therapy of
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
Primary Efficacy Objective -To assess whether a 12-week treatment course with oral 50 mg elbasvir plus 100 mg grazoprevir given in a single daily dose to treatment-naïve patients with end-stage renal disease (ESRD) and infected…
- Trial name
- CLEAR-C4 (NCT03381859)
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
- Where
- Egypt
- Sponsor
- University of Maryland, Baltimore
Acute on Chronic Hepatic Failure
Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure
50 patients of Acute-on-chronic liver failure (ACLF) will be enrolled and randomized into G-CSF+EPO or Placebo arms Treatment protocol To administer G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and…
- Trial name
- NCT01383460
- Testing
- Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)
- Where
- India
- Volunteers
- 55 people
- Sponsor
- Institute of Liver and Biliary Sciences, India